AI-generated · cited to primary sources · not investment advice
Aurobindo Pharma (524804) Nov 2025 Filing Analysis
Does management do what it says?
The company confirmed that Dazublys (trastuzumab biosimilar) received marketing authorization from the European Commission. (3 met, 1 revised, 1 in progress across 5 tracked commitments)
“BP16 (Prolia biosimilar) met Phase 3 endpoints in a clinical study across 5 European countries, ready for regulatory submission in the next Quarter.”
The company generated $118 million in free cash flows during Q3FY26, exceeding the $100 million quarterly target. (2 exceeded, 2 missed, 1 met across 5 tracked commitments)
“Last but not least, we are confident of achieving our internal margin target of 20%-21% for FY26, as communicated earlier.”
The facility has reached an annualized production level of 9,000 to 10,000 metric tonnes as of January 2026, indicating significant progress toward the 15,000 MT target. (1 in progress across 1 tracked commitment)
“which will support the further ramp-up in achieving 100% capacity utilization, taking the production to 15,000 MT in a very short term.”
The European business showed strong momentum with 27.4% YoY growth in Q3FY26, reaching ₹2,703 Cr for the quarter. (3 in progress across 3 tracked commitments)
“With consistent performance across all major markets, we are firmly on track to comfortably support the 1 billion annual revenue milestone from Europe by the end of FY26.”
The company expects USFDA inspection for biosimilar facilities to occur by the end of calendar year 2026. — target: Inspection
“So, if we file it somewhere between April-June, then I expect the inspection to happen by the end of the Calendar Year 2026 with the USFDA.”
See the full cited Management analysis of Aurobindo Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.